

Uspensky O. E., Pustovoi P. I. Clinical studies of phytoegel "Kvertulidon" stomatoprotective action in patients with helicobacter gastritis. Journal of Education, Health and Sport. 2019;9(7):423-428. eISSN 2391-8306. DOI <http://dx.doi.org/10.5281/zenodo.3352319>  
<http://ojs.ukw.edu.pl/index.php/johs/article/view/7192>  
<https://pbn.nauka.gov.pl/sedno-webapp/works/919562>

The journal has had 7 points in Ministry of Science and Higher Education parametric evaluation. Part B item 1223 (26/01/2017).  
1223 Journal of Education, Health and Sport eISSN 2391-8306 7

© The Authors 2019;  
This article is published with open access at Licensee Open Journal Systems of Kazimierz Wielki University in Bydgoszcz, Poland  
Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.  
(<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.  
The authors declare that there is no conflict of interest regarding the publication of this paper.  
Received: 05.07.2019. Revised: 20.07.2019. Accepted: 26.07.2019.

UDK 616.33:342.092

## CLINICAL STUDIES OF PHYTOGEL "KVERTULIDON" STOMATOPROTECTIVE ACTION IN PATIENTS WITH HELICOBACTER GASTRITIS

O. E. Uspensky<sup>1</sup>, P. I. Pustovoi<sup>2</sup>

<sup>1</sup>State Establishment «The Institute of Stomatology and Maxillo-Facial Surgery of the National Academy of Medical Science of Ukraine» (Odessa, Ukraine)

<sup>2</sup>Municipal Institution «Odessa Regional Clinical Hospital» (Ukraine)

[flavan.ua@gmail.com](mailto:flavan.ua@gmail.com)

### Abstract

Background. To determine the therapeutic and prophylactic effect of oral applications of the Kvertulidon phytoegel on the condition of the oral cavity in patients with Helicobacter gastritis.

Methods. A total of 28 patients with a diagnosis of gastritis of Helicobacter pylori and 18 healthy individuals were surveyed. Phytoegel was used as oral applications for 15 days. Hygiene and dental indices were determined, and the level of biochemical markers of inflammation, dystrophy and defenses in the oral fluid: elastase, catalase, urease, lysozyme activity, MDA content, API index and degree of dysbiosis.

Results. A significant increase in all hygienic and dental indices was found in patients with gastritis with a decrease in the level of catalase and lysozyme. Applications of phytoegel

reduce the activity of elastase, urease, the content of MDA, the degree of dysbiosis and increase the activity of catalase, lysozyme, and the API index.

Conclusion. Phytogel "Kvertulidon" has stomatoprotective effect in patients with helicobacter gastritis.

**Key words:** gastritis, *H. pylori*, oral cavity, saliva, phytogel, anti-helicobacter therapy.

## **INTRODUCTION**

It has been established that in patients with *Helicobacter pyloric* infection not only gastritis develops, but inflammatory and dystrophic processes occur in the tissues of the oral cavity (stomatitis, gingivitis) [1–4]. The experiment showed that the multifunctional antidisbiosis agent Kvertulidon, which includes quercetin, inulin, imudon and calcium citrate [5], has a therapeutic and prophylactic effect not only on the gastric mucosa, but also on the oral mucosa (oral mucosa) [6, 7].

We have shown that antihelicobacter therapy plays a significant role in the development of dental complications in gastritis [8].

The purpose of this exploration was to determine the therapeutic efficacy of the phytogel "Kvertulidon" in the case of dental complications of gastritis and its anti-helicobacter therapy.

## **MATERIAL AND RESEARCH METHODS**

In the work was used mucozo-adhesive phytogel "Kvertulidon" produced by the SPA "Odessa Biotechnology" [5].

Twenty eight patients with a diagnosis of chronic gastritis were surveyed, 93% of whom had a positive urease test, indicating the presence of *H. pylori* [6, 7].

18 people (men and women aged 19–42 y.o.) without somatic and serious dental pathology served as controls.

The diagnosis of gastritis was established by the doctors of the surgical department. All patients with gastritis received standard anti-helicobacter therapy (AHBT), which included omeprazol, amoksil, claritromycin [9].

Phytogel "Kvertulidon" was used in the form of daily oral applications in a dose of 0.5 ml twice a day (morning and evening, after meals) for 15 days.

The condition of the oral cavity was assessed by determining the hygienic and dental indices [10]. The following indicators were determined: Silness-Loe, Stalland, Schiller-Pisarev indices, PMA index.

All patients were collected oral fluid on an empty stomach [11] at admission and after 2 weeks. The level of biochemical markers of inflammation [12] was determined in saliva: elastase activity [13], malondialdehyde (MDA) content [14], catalase antioxidant enzyme activity [15], microbial semination index urease activity [16], biochemical marker activity of nonspecific lysozyme immunity [17].

The antioxidant-prooxidant index API was calculated by the ratio of catalase activity and MDA content [12], and the degree of dysbiosis by A. P. Levitsky [18] was calculated by the ratio of relative activities of urease and lysozyme.

The research results were subjected to standard statistical processing [19].

## RESULTS AND DISCUSSION

Table 1 presents the results of determining the condition of the oral cavity of patients with gastritis who received oral applications of the Kvertulidon phytogel.

Table 1. Clinical and laboratory indicators of the oral cavity in patients with gastritis who received oral applications of the Kvertulidon phytogel

Indicators	Control n=18	Gastritis, n=28	
		before treatment	after treatment
Salivation, ml / min	0,68±0,13	0,89±0,14 p>0,05	0,73±0,12 p>0,3; p <sub>1</sub> >0,05
Index Silness-Loe	0,3±0,1	2,3±0,3 p<0,01	0,9±0,3 p<0,05; p <sub>1</sub> <0,05
Index Stallard	0,4±0,2	1,9±0,5 p<0,05	0,5±0,2 p>0,5; p <sub>1</sub> <0,05
Schiller-Pisarev Index	0,8±0,3	2,5±0,4 p<0,05	1,1±0,3 p>0,3; p <sub>1</sub> <0,05
PMA, %	10±0,2	39±4 p<0,01	19±4 p<0,05; p <sub>1</sub> <0,01

Notes: p – in comparison with the control; p<sub>1</sub> - in comparison with the group "Before treatment".

It is seen that in all patients the level of all indices increases significantly, indicating the development of pathological processes in the tissues of the oral cavity. Oral phyto-gel applications reliably reduce the level of all indices, and the Stalland and Schiller-Pisarev indices practically returned to the control group.

Table 2 presents the results of determining the biochemical parameters of the oral fluid of patients. From these data it can be seen that the level of inflammatory markers (elastase and MDA) increases 3-4 times in patients with gastritis.

Table 2. Biochemical parameters of oral fluid in patients with gastritis, treated with phyto-gel "Kvertulidon"

Indicators	Control n=18	Gastritis, n=28	
		before treatment	after treatment
Elastase, mk-kat/l	0,27±0,02	0,87±0,05 p<0,01	0,33±0,04 p>0,05; p <sub>1</sub> <0,01
MDA, mmol/l	0,44±0,05	1,94±0,09 p<0,01	1,03±0,06 p<0,05; p <sub>1</sub> <0,05
Katalase, mkat/l	0,61±0,02	0,48±0,03 p<0,05	0,57±0,03 p>0,3; p <sub>1</sub> <0,05
API	13,9±0,97	2,5±0,33 p<0,01	5,5±0,6 p<0,01; p <sub>1</sub> <0,05
Urease, mk-kat/l	0,08±0,03	0,89±0,09 p<0,01	0,28±0,08 p<0,05; p <sub>1</sub> <0,05
Lysozyme, un./l	85±10	43±8 p<0,05	71±7 p>0,1; p <sub>1</sub> <0,05
Degree of dysbiosis	1,00±0,14	22,19±3,11 p<0,01	4,17±0,53 p<0,05; p <sub>1</sub> <0,01

Notes: see tab. 1.

Urease activity increases even more (11 times), indicating the growth of microbial semination of the oral cavity. At the same time, lysozyme activity decreases by 2 times, which indicates a decrease in the level of nonspecific immunity. As a result, in patients with gastritis

who received AHBT (anti-helicobacter therapy), the degree of oral dysbiosis increases by 22 times. Oral phytogel applications reliably reduce elastase, MDA, urease, and the degree of dysbiosis, but do not return them to normal values.

On the contrary, the application of phytogel normalized the activity of catalase and lysozyme, significantly increased the API index.

Thus, our researches have shown that patients with Helicobacter gastritis in the oral cavity develop pathological processes characteristic of stomatitis and gingivitis, by reducing the level of antioxidant and antimicrobial protection.

Inclusion in the complex of therapeutic measures for gastritis (AHBT) oral applications of the phytogel "Kvertulidon" allows to significantly reduce the level of pathological changes in the tissues of the oral cavity.

### **CONCLUSIONS**

1. In patients with the helicobacter etiology gastritis, inflammatory and dystrophic processes are observed in the oral cavity.

2. The use of phytogel "Kvertulidon" has a stomatoprotective effect during gastritis and their treatment.

### **REFERENCES**

1. Pattison CPh., Combs MF., Marshall BF. Helicobacter pylori and peptic ulcer disease: evolution to revolution to resolution. American Journal of Poentgenology. 1997; 168 (6): 1415-1420.

2. Baryshnikova NV. Actual problems of helicobacteriosis diagnosis. Experimental and clinical gastroenterology. 2009; 2: 50-56. (in Russian)

3. Tsodikov G. V., Zyakun A. M., Klimova E. V. Achievements and perspectives of studying Helicobacter pylori-infection. Epidemiology and Infectious Diseases. 2011; 2: 46-49. (in Russian)

4. Nenkovsky S., Ivakhnenko A. Comparative efficacy of major schemes of Helicobacter therapy in children. Medicines Ukraine. 2004; 11: 75-78. (in Ukrainian)

5. The "Kvertulidon" phytogel RC U 20.4-13903778-032/8:2015 for TU U 20.4-13903778-032:2012. Hygienic conclusion of the State Service of Ukraine for food safety and Consumer Protection № 05/03/02-07/15522; 10.04.2015. (in Ukrainian)

6. Bogatu SI, Iaremenko II, Liubchenko EA [and others]. The mouth state in gastritis patients. *Announcer of stomatology*. 2017; 4(101): 5-9. (in Ukrainian)
7. Bogatu SI, Iaremenko II, Liubchenko EA [and others]. The mouth state in gastroduodenit patients. *Announcer of stomatology*. 2018; 27(1(102): 28-31. (in Ukrainian)
8. Levitsky AP., Makarenko OA., Selivanskaya IA. [and others]. The therapeutic effect of the antidysbiotic drug "Quertulidon" on the state of the oral tissues of rats at anti-H. pylori therapy. *Actual problems of transport medicine*. 2015; 2 (40): 137-145. (in Russian)
9. Svintsitsky AS, Solovyov GA, Couric EG [and others]. Comparative efficacy of schemes of eradication therapy. *Modern Gastroenterology*. 2015; 2 (82): 7-14. (in Russian)
10. Mashchenko IS. *Paradontal diseases*. Dneproptrvsk, KOLO, 2003: 272. (in Russian)
11. Levitsky AP, Makarenko OA, Rossakhanova LN. Salivation in healthy people of different age and in stomatological patients. *Announcer of stomatology*. 2005; 2: 7-8. (in Russian)
12. Levitsky AP, Denga OV, Makarenko OA [and others]. *Biochemical markers of inflammation of oral cavity tissue: method guidelines*. Odessa, KP OGT, 2010: 16. (in Russian)
13. Levitsky AP, Stefanov AV. *The methods of the determination of the activity of elastase and its inhibitors: method guidelines*. Kiev, GFK, 2002:15. (in Russian)
14. Stalnaya ID, Garishvili TG. *The method of revelation of malonic dialdehyde with thiobarbituric acid*. Moskva, Meditsina, 1977: 66-68. (in Russian)
15. Girin SV. *The modification of the method of the determination of catalase activity in biological substrates*. *Laboratory diagnostics*. 1999; 4: 45-46. (in Russian)
16. Gavrikova LM., Segen IT. *Urease activity of oral liquid in patients with acute odontogenic infection of maxillo-facial part*. *Stomatology*. 1996; The extra issue: 49-50. (in Russian)
17. Levitsky AP. *Lysozyme instead of antibiotics*. Odessa, KP OGT, 2005: 74. (in Russian)
18. Levitsky AP, Makarenko OA, Selivanskaya IA [and others]. *Enzymatic methods for determination of oral dysbiosis for screening pro- and prebiotics: method guidelines*. Kiev, GFC, 2007: 22. (in Russian)
19. Truhacheva NV. *Mathematical Statistics in biomedical research using application package Statistica*. Moscow, GJeOTAR-Media, 2012: 379. (in Russian)